We are a Biomedical Engineering Master’s student team from Université de Paris. As a part of the worldwide synthetic biology competition iGEM 2021, we are creating an easy-to-use cancer screening solution that could complement any routine laboratory analysis.
Early-stage cancer diagnosis can improve patient survival across a range of aggressive tumours. Yet, the patient is often referred to an oncologist after the disease has already progressed. Biofluid analysis, e.g. blood or urine, is a potential solution to this problem, as it is a simpler, non-invasive, and flexible alternative to tissue biopsy.
Our goal is to employ synthetic biology and build a simple and efficient microfluidic chip, which detects a panel of cancer-associated molecules in a few drops of a patient’s blood. Watch this space if you want to learn more!
Follow us on various social media for different updates and project-related news!
Instagram: https://www.instagram.com/igem_uparis/
Facebook: https://www.facebook.com/uparis.igem
Twitter: https://twitter.com/IGEM_UParis
Company Details
- Founded
- 2021
- Address
- 45, Rue Des Saints-Pères, P409,france
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Keywords
- Oncology, Diagnostics, Synthetic Biology, iGEM, Cancer, Liquid Biopsy, Microfluidics, Exosome, miRNA.
- HQ
- Paris, Île-de-France
- Competitors
- Pitchy, Germen, Junior BIOS.
Igem Université De Paris Questions
Igem Université De Paris's LinkedIn profile is https://fr.linkedin.com/company/igem-uparis
Igem Université De Paris's industry is
Biotechnology Research
Igem Université De Paris's categories are Biotechnology Research
Igem Université De Paris's founding year is 2021
